← The Procter & Gamble Company
PG · Forward model · Bull case
The Bull case, 20 quarters out
Model as of
Each segment is projected from its own operating driver, rolled up into consolidated cash flow, and discounted back to a fair value per share. The assumptions below are editable — change them and every number on this page moves with them.
Every revenue line here is a reportable segment P&G discloses, not an apportionment. The five operating segments plus Corporate sum to reported consolidated net sales in all twenty quarters, with a largest residual of $2m on $21bn - P&G's own rounding in its $-million segment table. Sixteen of the twenty quarters per line are read from a filed segment table; the four April-June quarters are derived as fiscal-year segment total less the disclosed nine-month segment column and are marked estimated, and the most recent of them is independently confirmed line by line in the Q4 fiscal 2026 8-K. NOT disclosed and therefore not modelled: any dollar split of a segment into its named categories - P&G publishes only whole-percent-of-company shares such as 'Fabric Care 23%' - any geographic split below US and international totals, any unit, volume or household count, and any allocation of restructuring cost to a segment. Because P&G discloses no operational level for any segment, every vertical uses the growth driver; the volume, currency, price, mix and acquisition percentages the company does publish are evidence for the rate, not a level to model. Segment EBITDA margins are fiscal 2026 GAAP figures - (segment earnings before income taxes + segment depreciation and amortisation) / segment net sales - because segment D&A is disclosed annually only; the June quarter itself was restructuring-depressed at 18.6% GAAP operating margin against 19.5% core. The whole of the restructuring programme, the interest line and the unallocated overhead sit in the Corporate vertical, so corporate.overheadPctRevenue is zero to avoid counting them twice. The 20% tax rate is P&G's guided fiscal 2027 core effective rate. Consensus EPS for this company is a core figure and must never be paired with the site's stored GAAP EPS: the June quarter's $1.43 core beat a $1.41-$1.42 street number, while GAAP was $1.26.
Shares this page's scenario. Driver and horizon edits stay in your browser — the recipient sees the published model.
Latest: $26.20B (2031Q2E)
| Period | Value |
|---|---|
| 2021Q3 | $20.34B |
| 2021Q4 | $20.95B |
| 2022Q1 | $19.38B |
| 2022Q2 | $19.52B |
| 2022Q3 | $20.61B |
| 2022Q4 | $20.77B |
| 2023Q1 | $20.07B |
| 2023Q2 | $20.55B |
| 2023Q3 | $21.87B |
| 2023Q4 | $21.44B |
| 2024Q1 | $20.20B |
| 2024Q2 | $20.53B |
| 2024Q3 | $21.74B |
| 2024Q4 | $21.88B |
| 2025Q1 | $19.78B |
| 2025Q2 | $20.89B |
| 2025Q3 | $22.39B |
| 2025Q4 | $22.21B |
| 2026Q1 | $21.23B |
| 2026Q2 | $21.20B |
| 2026Q3E | $22.62B |
| 2026Q4E | $22.66B |
| 2027Q1E | $21.57B |
| 2027Q2E | $22.12B |
| 2027Q3E | $23.60B |
| 2027Q4E | $23.64B |
| 2028Q1E | $22.50B |
| 2028Q2E | $23.07B |
| 2028Q3E | $24.63B |
| 2028Q4E | $24.66B |
| 2029Q1E | $23.46B |
| 2029Q2E | $24.07B |
| 2029Q3E | $25.70B |
| 2029Q4E | $25.73B |
| 2030Q1E | $24.48B |
| 2030Q2E | $25.11B |
| 2030Q3E | $26.82B |
| 2030Q4E | $26.85B |
| 2031Q1E | $25.53B |
| 2031Q2E | $26.20B |
Where each case comes from
Bear case — primary sources
The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Bear column is what happens if they are taken at face value.
What the June quarter actually printed
- Jul 29, 2026 Organic sales, which exclude the impacts of foreign exchange and acquisitions and divestitures, were unchanged versus the prior year.
- Jul 29, 2026 Included in this organic sales growth guidance is a headwind of 30 to 50 basis points from brand, product form and go-to-market discontinuations.
The cost headwind, and where it lands
Bull case — primary sources
The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Bull column is what happens if they are taken at face value.
What the reinvestment is buying, in the CFO's words
The guided range this case sits inside
- Jul 29, 2026 P&G expects fiscal year 2027 all-in sales growth in the range of one to three percent versus the prior year.
- Jul 29, 2026 core earnings per share growth in the range of in-line to three percent versus fiscal 2026 core EPS of $6.89. This outlook equates to a range of $6.89 to $7.11 per share, with a mid-point estimate of $7.00.
Jejurikar case — primary sources
The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Jejurikar column is what happens if they are taken at face value.
The semester-to-semester claim
- Aug 7, 2026 we do expect to have the cost anniversaried as we go into the back half as well as have continued sequential improvements in our top-line as we move forward
- Jul 29, 2026 We are confident in our plans to accelerate growth from semester-to-semester, and our investments will be funded with a strong productivity program.
From cash flow to fair value
The published model, discounted at 7.0% a year with an exit multiple of 17.0x on EBITDA. The sliders above do not change this walk.
| Present value of free cash flow, 20 quarters | $70.98B |
| Terminal-year revenue | $105.40B |
| Terminal-year EBITDA | $28.43B |
| Exit multiple, on EBITDA | 17.0x |
| Terminal value | $483.34B |
| Discounted at 7.0% a year, terminal value becomes | $344.61B |
| Share of enterprise value from the terminal | 83% |
| Enterprise value | $415.59B |
| Net cash | −$24.20B |
| Equity value | $391.39B |
| Shares | 2.32B |
| Fair value per share | $168.38 |
| Against the deployed price of $142.97, as of | +18% |
P&G trades at 15.77x trailing EBITDA: an enterprise value of $361.2bn - $337.0bn of market capitalisation on 2,324,433,060 shares at $145.00, plus $24.2bn of net debt - over fiscal 2026 EBITDA of $22,908m, which is reported operating income of $19,748m plus $3,160m of depreciation and amortisation. That is 21.9x trailing GAAP EPS of $6.62 and 20.7x the $7.00 core guidance midpoint; StockAnalysis independently shows 21.89x and 20.75x. The base case exits at 15.0x, a shade below today's rating, because a terminal multiple should not assume the current one survives five years on a company whose June-quarter organic sales growth was zero with volume, price and mix all flat. The 7.0% discount rate is a staples cost of capital for an A-rated issuer on a 3.0% dividend yield; P&G discloses no WACC. This one assumption dominates: $267.3bn of the base case's $333.4bn enterprise value, 80%, is the discounted exit multiple, and one turn of EBITDA on the $24.99bn terminal year is $17.8bn once discounted, about $7.66 a share.
Read the other way round: at $142.97 the market is paying 14.1x terminal-year EBITDA, holding every other assumption on this page fixed. That is the number to argue about.
The projected path
| Quarter | Beauty | Grooming | Health Care | Fabric & Home Care | Baby, Feminine & Family Care | Corporate | Revenue | YoY | EBITDA | Capex | FCF | R40 | PV of FCF |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3E | $4.41B | $1.79B | $3.21B | $7.84B | $5.09B | $295M | $22.62B | +1% | $5.96B | $1.14B | $3.85B | +18 | $3.79B |
| 2026 Q4E | $4.29B | $1.81B | $3.40B | $7.74B | $5.13B | $298M | $22.66B | +2% | $6.03B | $1.14B | $3.91B | +19 | $3.78B |
| 2027 Q1E | $3.96B | $1.60B | $3.08B | $7.45B | $5.17B | $300M | $21.57B | +2% | $5.76B | $1.10B | $3.73B | +19 | $3.55B |
| 2027 Q2E | $4.22B | $1.77B | $2.88B | $7.73B | $5.21B | $303M | $22.12B | +4% | $5.93B | $1.12B | $3.85B | +22 | $3.59B |
| 2027 Q3E | $4.68B | $1.86B | $3.35B | $8.15B | $5.25B | $306M | $23.60B | +4% | $6.35B | $1.18B | $4.13B | +22 | $3.79B |
| 2027 Q4E | $4.56B | $1.88B | $3.55B | $8.05B | $5.30B | $309M | $23.64B | +4% | $6.37B | $1.19B | $4.15B | +22 | $3.75B |
| 2028 Q1E | $4.21B | $1.67B | $3.22B | $7.75B | $5.34B | $312M | $22.50B | +4% | $6.06B | $1.14B | $3.94B | +22 | $3.50B |
| 2028 Q2E | $4.49B | $1.84B | $3.01B | $8.04B | $5.38B | $315M | $23.07B | +4% | $6.22B | $1.17B | $4.04B | +22 | $3.53B |
| 2028 Q3E | $4.98B | $1.94B | $3.50B | $8.48B | $5.42B | $318M | $24.63B | +4% | $6.64B | $1.23B | $4.33B | +22 | $3.72B |
| 2028 Q4E | $4.84B | $1.96B | $3.71B | $8.37B | $5.47B | $321M | $24.66B | +4% | $6.66B | $1.24B | $4.34B | +22 | $3.66B |
| 2029 Q1E | $4.47B | $1.73B | $3.36B | $8.06B | $5.51B | $324M | $23.46B | +4% | $6.33B | $1.19B | $4.12B | +22 | $3.42B |
| 2029 Q2E | $4.77B | $1.92B | $3.14B | $8.36B | $5.56B | $327M | $24.07B | +4% | $6.49B | $1.21B | $4.22B | +22 | $3.45B |
| 2029 Q3E | $5.29B | $2.02B | $3.65B | $8.82B | $5.60B | $330M | $25.70B | +4% | $6.93B | $1.28B | $4.52B | +22 | $3.63B |
| 2029 Q4E | $5.14B | $2.04B | $3.87B | $8.70B | $5.64B | $333M | $25.73B | +4% | $6.95B | $1.29B | $4.53B | +22 | $3.57B |
| 2030 Q1E | $4.75B | $1.81B | $3.51B | $8.39B | $5.69B | $337M | $24.48B | +4% | $6.60B | $1.23B | $4.30B | +22 | $3.33B |
| 2030 Q2E | $5.06B | $2.00B | $3.28B | $8.70B | $5.74B | $340M | $25.11B | +4% | $6.77B | $1.26B | $4.41B | +22 | $3.36B |
| 2030 Q3E | $5.62B | $2.10B | $3.81B | $9.17B | $5.78B | $343M | $26.82B | +4% | $7.23B | $1.33B | $4.72B | +22 | $3.54B |
| 2030 Q4E | $5.46B | $2.12B | $4.04B | $9.05B | $5.83B | $346M | $26.85B | +4% | $7.25B | $1.34B | $4.73B | +22 | $3.49B |
| 2031 Q1E | $5.04B | $1.88B | $3.66B | $8.72B | $5.87B | $350M | $25.53B | +4% | $6.89B | $1.28B | $4.48B | +22 | $3.25B |
| 2031 Q2E | $5.38B | $2.08B | $3.42B | $9.04B | $5.92B | $353M | $26.20B | +4% | $7.06B | $1.31B | $4.60B | +22 | $3.28B |
Every row is projected. A year-over-year change is shown only where the quarter it compares against exists — an em dash means there is no comparable quarter, not a flat year.
Model revisions
Assumptions are marked to reality as each quarter prints. Every change is appended here, with the fair value the model produced at the time, so the model's own history stays visible.
| Date | Fair value then | Note |
|---|---|---|
| 2026-08-27 | $133.02 | First published model. Built on the fiscal 2026 fourth quarter reported 29 July 2026: six disclosed segment lines across twenty quarters, four-factor seasonality on the four segments where the derived shape beats its own window-to-window spread, and a base case pinned to trailing deseasonalised growth rather than to guidance. |